{"filing":{"accession_number":"0001213900-26-079822","cik":"0001871321","ticker":"DRTSW","company_name":"Alpha Tau Medical Ltd.","form":"6-K","filing_date":"2026-07-21","report_date":null,"primary_document":"ea0298609-6k_alpha.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1871321/000121390026079822/ea0298609-6k_alpha.htm"},"events":[{"id":18986,"run_id":17086,"accession_number":"0001213900-26-079822","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces positive clinical trial results for Alpha DaRT in combination with pembrolizumab in head and neck cancer, demonstrating a 100% objective response rate and 18.2-month median overall survival that exceed pre-specified thresholds and historical benchmarks. While the disclosure reports clinical progress rather than a discrete corporate event (M\u0026A, executive change, debt issuance, etc.), the achievement of a major clinical milestone with favorable efficacy and safety data in a key indication materially advances the company's pipeline and regulatory strategy, directly supporting its stated plan to pursue larger U.S. studies in discussion with the FDA.","company_name":"Alpha Tau Medical Ltd.","ticker":"DRTSW","filing_date":"2026-07-21","form":"6-K","submitted_at":null,"items":[{"id":17956,"accession_number":"0001213900-26-079822","item_number":"EX-99.1","item_title":"ea029860901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces positive clinical trial results for Alpha DaRT in combination with pembrolizumab in head and neck cancer, demonstrating a 100% objective response rate and 18.2-month median overall survival that exceed pre-specified thresholds and historical benchmarks. While the disclosure reports clinical progress rather than a discrete corporate event (M\u0026A, executive change, debt issuance, etc.), the achievement of a major clinical milestone with favorable efficacy and safety data in a key indication materially advances the company's pipeline and regulatory strategy, directly supporting its stated plan to pursue larger U.S. studies in discussion with the FDA.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-21T12:30:48.929428+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17956,"accession_number":"0001213900-26-079822","item_number":"EX-99.1","item_title":"ea029860901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces positive clinical trial results for Alpha DaRT in combination with pembrolizumab in head and neck cancer, demonstrating a 100% objective response rate and 18.2-month median overall survival that exceed pre-specified thresholds and historical benchmarks. While the disclosure reports clinical progress rather than a discrete corporate event (M\u0026A, executive change, debt issuance, etc.), the achievement of a major clinical milestone with favorable efficacy and safety data in a key indication materially advances the company's pipeline and regulatory strategy, directly supporting its stated plan to pursue larger U.S. studies in discussion with the FDA.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-21T12:30:48.929428+00:00","company_name":"Alpha Tau Medical Ltd.","ticker":"DRTSW","filing_date":"2026-07-21"}]}